Printer Friendly

Virtual screening of coformers and solubility test for glibenclamide cocrystallization.


The therapeutic effectiveness of active pharmaceutical ingredients (API) depends on their solubility. API, which has poorly soluble drugs, can cause low bioavailability.[1,2] This study previously shows that crystal engineering can improve the solubility and dissolution rate, which impacts bioavailability. The API crystal forms possess undesirable physical properties, and hence, there is a need for the development of a crystalline form of APIs with desired physicochemical properties. [3]

Glibenclamide, one of the APIs, has poor solubility in water. This property can lead to poor dissolution rate and subsequent decrease of its gastrointestinal absorption. In the biopharmaceutical classification system, glibenclamide, included in Class II, has a high permeability but a low solubility, because of that, the absorption of glibenclamide was limited, according to its dissolution rate. [4] Several methods have been studied to increase the solubility of glibenclamide, such as the solid dispersion method, [5] surface solid dispersion, nanoparticles, [6] and nanoemulsion. [7] The disadvantage of these methods is less stable when made in a solid preparation, so the dissolution rate of glibenclamide is incompatible with its bioavailability. [8]

Several methods have been studied to increase the solubility of glibenclamide such as solid dispersion method, [5] surface solid dispersion, nanoparticles, [6] and nanoemulsion. [7] The disadvantages of these methods are less stable when made in a solid preparation, thus increasing the dissolution rate of glibenclamide is incompatible with its bioavailability. [8]

One method that can improve the solubility is cocrystal. Cocrystal cocrystallization is a one method to improve the physical property that structurally crystalline material containing component presents in a definite stoichiometric amount 1,4. To predict the ability of API, a coformer can be formed into a cocrystal, and it can be used for experimental screening. We can also use virtual screening. One approach is to analyze the structures of crystalline solids based on the pairing of H-bond donors and acceptors. [9] The study shows that molecular electrostatic potential surfaces can be used to rank the relative H-bond donor/acceptor strengths of different functional groups, and this approach has been used to predict the formation of ternary cocrystals. [10]

In this paper, we apply this approach to the solid state to estimate the probability of cocrystal formation using virtual screening, and then, to study the solubility and dissolution test of one of the best coformers.


Hardware and Programs

Personal computers equipped with Intel Core i5 2.30 GHz processor DRAM 4 GB was used in this work. Programs were SPORES, Open Babel GUI 2.2.3, PLANTS1.2, and MGL Tools1.5.6 shell script for the initial preparation of the ligands and Auto Dock 4.2.3 for docking process. [11,12]

Molecular Docking

2D structures of glibenclamide (Chem Spider ID: 54809) and its coformers in. mol format were downloaded from All. mol files of the molecules were converted into. pdb files by employing OpenBabelGUI 2.2.3. The files were then opened in AutoDock 4.2.3 and converted into.pdbq files by adding polar hydrogen and Kollman charges. The. pdbq files were converted into. pdbqt by calculating their torsion angles and were ready to be used for docking. Docking was repeated 5 times for each coformer. Parameters observed were the type and energy (Ei) of interactions. [11,12]

Preparation of the Glibenclamide Cocrystal

The glibenclamide cocrystal was prepared by the dry grinding method and taking component 1:1 and molar ratio (glibenclamide BM 494: Oxalic acid BM 126).

Determination of Solubility

Around 50 mg of glibenclamide was placed in Erlenmeyer containing Aquadest. These were agitated in a mechanical shaker for 24 h at room temperature. The saturated solutions were filtered through a 0.45 [micro]m membrane filter, and the amount of the drug dissolved were analyzed spectrophotometrically at 266 nm. [1]

The Dissolution Test

In vitro dissolution studies of pure glibenclamide and glibenclamide-oxalic acid were conducted with the USP Type II apparatus (paddle type). The studies used 900 ml of a buffer phosphate with a pH of 8 and USP apparatus 2 with an agitation rate of 75 rpm. Samples of each preparation equivalent to 50 mg of drug were added into the dissolution medium. The sample was measured periodically (0, 10, 15, 30, 45, and 60 min) and was analyzed spectrophotometrically at 266 nm. [13,14]


The structure of glibenclamide can be seen in Figure 1. The result of virtual screening of coformer for glibenclamide can be seen in Table 1.

The prediction of cocrystal formation of glibenclamide oxalic acid can be seen in Figure 2.

Interaction between glibenclamide and oxalic acid using 2D docking method can be seen in Figure 3.

The result solubility studies of glibenclamide cocrystal using oxalic acid can be seen in Table 2.

The result of dissolution test from glibenclamide cocrystal can be seen in Table 3 and Figure 4.


The molecule of glibenclamide contains two aromatic, 1 hydrogen bond acceptors and 2 hydrogen bond donors (HBDs) (HBDs, and hence, it is possible to form cocrystals with certain coformers. The coformers chosen in this work were ten coformers including fumaric acid, citric acid, ascorbic acid, formic acid, oxalic acid, benzoic acid, sulfamic acid, acetic acid, malic acid, and stearic acid.

For the solubility and dissolution test, oxalic acid was used as coformer because oxalic acid can interact through one hydrogen bond (Ei = -1,6 kcal/mol) with glibenclamide. The prediction of interaction between glibenclamide and oxalic acid can be seen in Figure 2.

The selection of cocrystal method used dry grinding method. This is a preliminary study so that no organic solvent is used in manufacturing glibenclamide cocrystal. The result showed that glibenclamide oxalic acid increases the solubility compared to pure glibenclamide. In Table 2, glibenclamide oxalic acid increases 94.8% after 12 h and 81.6% after 24 h compared to pure glibenclamide. The increased solubility of glibenclamide occurs due to the formation of hydrogen bonds between glibenclamide and oxalic acid. [15]

Table 3 showed that glibenclamide has better curve (47.12% in 10 min, 75.05% in 30 min, and 77.3% in 60 min) than pure glibenclamide (27.82% in 10 min, 31.72% in 30 min, and 44.52% in 60 min). This indicates that solubility data are complementary of dissolution, if cocrystal solubility is increased in comparison to pure or standard; intrinsic dissolution is also improved for cocrystals in comparison with pure or standard. [16]


Based on molecular docking, the best of three coformers were oxalic acid (Ei = -1,6 kcal/mol), benzoic acid (Ei = -2,6 kcal/mol), and ascorbic acid (Ei = -2,1 kcal/mol). The result of the solubility test showed that glibenclamide oxalic acid increases 181.7% compared to pure glibenclamide at 24 h. The result of the dissolution test showed that glibenclamide oxalic acid has a better curve (77.3% in 60 min) than pure glibenclamide (44.52% in 60 min). This indicated that a coformer can increase the dissolution profile of glibenclamide by the approach cocrystalization method.


The authors thanks to Universitas Padjadjaran (Riset Fundamental Unpad 2017) for financial support in this research.


[1.] Vinesha V, Sevukarajan M, Rajalakshmi R, Chowdary GT, Haritha K. Enhancement of solubility of tadalafil by co crystal approach. Int Res J Pharm 2013;4:218-23.

[2.] Zaini E, Halim A, Soewandhi SN, Setyawan D. Increased trimethoprim solubility by co-crystallization method with nicotinamide. J Far Indonesia 2011;5:205-12.

[3.] Pathak CD, Savjani KT, Gajjar AK, Savjani JK. An efficient approach to enhance solubility. Int J Pharm Pharm Sci 2013;5:25-121.

[4.] Dastmalchi S, Garjani A, Maleki N, Sheikhee G, Baghchevan V, Jafari-Azad P, et al. Enhancing dissolution, serum concentrations and hypoglycemic effect of glibenclamide using solvent deposition technique. J Pharm Pharm Sci 2005;8:175-81.

[5.] Tabbakhian M, Hasanzadeh F, Tavakoli N, Jamshidian Z. Dissolution enhancement of glibenclamide by solid dispersion: Solvent evaporation versus a supercritical fluid-based solvent-antisolvent technique. Res Pharm Sci 2014;9:337-50.

[6.] Dora CP, Singh SK, Kumar S, DatusaliaAK, DeepA. Development and characterization of nanoparticles of glibenclamide by solvent displacement method. Acta Pol Pharm Drug Res 2010;67:283-90.

[7.] Bari A, Chella N, Sanka K, Shastri NR, Diwan PV. Improved anti-diabetic activity of glibenclamide using oral self nano emulsifying powder. J Microencapsul 2015;32:54-60.

[8.] Sohrab M, Mahapatra SP. Pharmaceutical co-crystal: A new paradigm for enhancing the physicochemical properties of active pharmaceutical ingredient. Int J Pharm Life Sci 2015;6:4324-33.

[9.] Musumeci D, Hunter CA, Prohens R, Scuderi S, McCabe JF. Virtual cocrystal screening. Chem Sci 2011;2:883-90.

[10.] Hunter CA. Quantifying intermolecular interactions: Guidelines for the molecular recognition toolbox. Angew Chem Int Ed 2004;43:5310-24.

[11.] Gozali D, Megantara S, Levita J, Bahti HH, Soewandhi SN, Abdassah M. Virtual screening of coformers for atorvastatin co-crystallization and the characterizations of the co-crystals. Int J Pharm Sci Res 2016;7:1450.

[12.] Siswandi S, Rusdiana T, Levita J. Virtual screening of co-formers for ketoprofen co-crystallization and the molecular properties of the co-crystal. J Appl Pharm Sci 2015;5:78-82.

[13.] Putra DO, Ilma N, Ibrahim S, Hidehiro U. Formation of Semi-crystalline solids and co-crystals from Paracetamol. J Mat Sains 2012;17:83-8.

[14.] Gianotto EA, Arantes RP, Lara-Filho MJ, Filho AC, Fregonezi-Nery MM. Dissolution test for glibenclamide tablets. Quim Nova 2007;30:1218-21.

[15.] Qiao N, Li M, Schlindwein W, Malek N, Davies A, Trappitt G. Pharmaceutical cocrystals: An overview. Int J Pharm 2011;419:1-11.

[16.] Yadav S, Gupta PC, Sharma N, Kumar J. Cocrystals: An alternative approach to modify physicochemical properties of drugs. Int J Pharma Chem Biol Sci 2015;5:427-36.

Arif Budiman, Sandra Megantara, Ayu Apriliani

Department of Pharmaceutical Sciences and Pharmaceutics, Faculty of Pharmacy, Universitas Padjadjaran, Jatinangor Sumedang, Indonesia

Correspondence to: Arif Budiman, E-mail:

Received: August 25, 2017; Accepted: September 29, 2017

How to cite this article: Budiman A, Megantara S, Apriliani A, Virtual screening of coformers and solubility test for glibenclamide cocrystallization. Natl J Physiol Pharm Pharmacol 2018;8(1):124-129.

Source of Support: Nil, Conflict of Interest: None declared.

DOI: 10.5455/njppp.2017.7.0833229092017
Table 1: Virtual screening of coformers for glibenclamide

Coformer       Structure 2D  Interaction  Ei (kcal/mol)

Fumaric acid                              -1.8 no interaction
Citric acid                               -2.1 no interaction
Ascorbic acid                             -2.1 1 hydrogen bond
Formic acid                               -1.3 2 hydrogen bond
Oxalic acid                               -1.6 1 hydrogen bond
Benzoic acid                              -2.6 1 hydrogen bond
Sulfamic acid                             -1.6 1 hydrogen bond
Acetic acid                               -1,5 1 hydrogen bond
Malic acid                                -1,9 1 hydrogen bond
Stearic acid                              -2,1 no interaction

Table 2: Solubility studies of glibenclamide cocrystal

Formula               Concentration of   Concentration of
                      glibenclamide (%)  glibenclamide (%)
                      at 12 h            at 24 h

Pure glibenclamide    3.32               4.53
Glibenclamide-oxalic  6.47               8.23

Table 3: Dissolution test of glibenclamide cocrystal

Times      Pure               Glibenclamide-oxalic
(minutes)  glibenclamide (%)  acid (%)

0           0                  0
5          19.87              18.24
10         27.82              47.12
15         27.9               61.94
30         31.72              75.06
45         36.7               75.76
60         44.52              77.3
COPYRIGHT 2018 Dipika Charan
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2018 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Author:Budiman, Arif; Megantara, Sandra; Apriliani, Ayu
Publication:National Journal of Physiology, Pharmacy and Pharmacology
Article Type:Report
Date:Jan 1, 2018
Previous Article:Dynamics of the content of free amino acids in blood of patients during the long-term use of orthopedic dental metal prostheses.
Next Article:Antimicrobial lotion containing red Piper betle leaf (Piper crocatum Ruiz and Pav) ethanolic extract for topical application.

Terms of use | Privacy policy | Copyright © 2021 Farlex, Inc. | Feedback | For webmasters